Search clinical trials for: HBV-MPL vaccine Formulation B

Total 1326 results

GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

Hepatitis B

Belgium, Canada, Sweden
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Hepatitis B

Denmark, Belgium
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Hepatitis B
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
GlaxoSmithKline

Active, not recruiting

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Hepatitis B, Chronic

Taiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Infections, Papillomavirus

Finland
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
GlaxoSmithKline

Completed

To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)

Infections, Rotavirus

Panama
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Cervical Cancer | HPV | Premalignancy Anogenital Warts
Norwegian Institute of Public Health
International Centre for Diarrhoeal Disease Research, Bangladesh; Sykehuset...

Completed

Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.

Hepatitis E Infection

Bangladesh
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
University of Pretoria
University of Stellenbosch

Active, not recruiting

Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (TheraVACCS)

Genital Warts

South Africa
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults (HVTN 097)

HIV Infection

South Africa
GlaxoSmithKline

Completed

Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants

Hepatitis B

Russian Federation
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Infections, Respiratory Syncytial Virus

Canada
Xiamen Innovax Biotech Co., Ltd

Completed

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)

Hepatitis B | Hepatitis E

China
GlaxoSmithKline

Completed

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Infections, Rotavirus

United States, Taiwan, Canada, Hong Kong, Turkey
Assiut University

Not yet recruiting

Efficacy of Accelerated Versus Standard Regiment of Hepatitis B Virus Vaccine Among Inflammatory Bowel Disease Patients

Inflammatory Bowel Diseases
Sanofi

Completed

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

Pneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal Pneumonia

Switzerland
GlaxoSmithKline

Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Respiratory Syncytial Virus Infections

Germany, Estonia, Belgium, France
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

COVID-19

Honduras, United States, Australia, France, New Zealand, Spain, United Kingdom
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation

Menopause
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
GlaxoSmithKline

Completed

Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination

Hepatitis B

Germany
ANRS, Emerging Infectious Diseases
Imperial College London; University College, London; Fred Hutchinson Cancer Center and other collaborators

Terminated

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection (EHVAT01)

HIV-1-infection

Switzerland, United Kingdom
Sun Xin

Active, not recruiting

Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes

Vaccine Adverse Reaction

China
Pfizer

Active, not recruiting

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons. It Will Be Given Twice Over a Period of Time to Healthy Adults

Clostridoides Difficile Associated Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Pneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal Pneumonia

Switzerland
GlaxoSmithKline

Completed

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Rotavirus Infection | Rotavirus Vaccines

United States
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile

3

Subscribe